Clinical Oncology Next-Generation Sequencing Market Overview:
The purpose of this report is to provide a thorough examination of the Clinical Oncology Next-Generation Sequencing Market by segments and geographics. The study goes into great detail on the primary factors influencing the Clinical Oncology Next-Generation Sequencing Market’s growth. The study also offers a comprehensive analysis of the market’s value chain.
To learn more, simply click on the link below@ https://www.maximizemarketresearch.com/request-sample/100383
Market Scope:
The “Global Clinical Oncology Next-Generation Sequencing Market Analysis” is a detailed investigation of the Clinical Oncology Next-Generation Sequencing Market, with a focus on global market trends and analysis. The goal of this research is to provide an overview of the Clinical Oncology Next-Generation Sequencing Market as well as detailed market segmentation by application, end-use, and geography. The Clinical Oncology Next-Generation Sequencing Market is expected to develop substantially over the forecast period. The study contains critical information on the market positions of the leading Cardiac Resynchronization Therapy Systems players, as well as noteworthy industry trends and opportunities.
Market Dynamics:
The market for next-generation sequencing in clinical oncology is anticipated to lead in the next years due to factors such as the rising incidence of cancer and technological advancements in the sector. Additionally, it is anticipated that during the anticipated era, a rise in the preference for NGS over single-gene research would present significant prospects for market expansion.
The United States saw 1.7 million new instances of cancer and 0.6 million cancer-related deaths in 2019, according to the American Cancer Society. The four most common cancers worldwide are female breast cancer, bladder cancer, prostate cancer, and lung cancer, together making up 43% of all new cancer cases. Thus, it is anticipated that the rise in cancer incidence rates worldwide would raise demand for next-generation sequencing in clinical oncology.
Segmentation:
by Technology
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing Centrifuges
With a sales share of more than 72% in 2020, the targeted sequencing and resequencing segment saw tremendous growth based on technology. The cost, time, and amount of data analysed during the sequencing of tumour samples are often reduced by targeted cancer sequencing panels. Furthermore, the therapeutic efficacy of targeted panels is enhanced by their capacity to detect malignant tumours. A 2020 JCO Precision Oncology research found that 64 percent of cancer cases can be treated clinically with NGS panels.
by Workflow
• Pre Sequencing
• Sequencing
• Data Analysis
Sequencing accounted for over 54% of overall revenue, making it the most profitable process category according to process. One of the most important stages of the workflow, sequencing calls for the usage of specialised platforms. The growth of the segment is further supported by an increase in the quantity of cancer sequencing programmes. The primary drivers of the pre-sequencing portion are the attempts of major stakeholders to lower the cost of NGS library planning. It is anticipated that NGS data analysis would become more common. The creation of advanced analytical tools by prominent industry players is driving the growth of this area. More than 2,600 tumour samples from 38 distinct cancer types were sequenced by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium.
by Application
• Screening
• Companion Diagnostics
• Other Diagnostics
According to the application, the screening generated the largest revenue share—more than 79%. It is currently believed that NGS-based research is the most efficient way to find genetic alterations in cancer patients that can be used to their advantage as a therapy. Physicians can now analyse many gene variants simultaneously thanks to this technology. Alliances and partnerships among important stakeholders, together with continuous product innovation, are expected to drive the adoption of NGS for companion diagnostics.
by End-User
• Hospitals
• Clinics
• Laboratories
Over the course of the projected period, the laboratories category emerged as the industry leader, accounting for over 65 percent of total sales, according to End User data. It takes a lot of time to set up dynamic workflows in laboratories. Because of this, most specialised labs have already created workflows based on standard operating procedures. Furthermore, thorough guidelines for processes requiring NGS testing have been built as a result of the quick development and distribution of NGS assays for clinical application. Because of this, the majority of FDA-approved evaluations demonstrate the validity of their conclusions through the use of tried-and-true controls, criteria, and performance attributes.
To know about the Research Methodology :- Simply Click on the link below
Key Players:
The major players covered in the Clinical Oncology Next-Generation Sequencing Market report are
• Illumina, Inc.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• F. Hoffman-La Roche Technologies
• Agilent Technologies
• Myriad Genetics
• Foundation Medicine
• Pacific Bioscience
• Oxford Nanopore Technologies Ltd.
• Beijing Genomics Institute (BGI)
• Perkin Elmer, Inc.
• Paradigm Diagnostics
• Caris Life Sciences
• Partek, Inc.
• Eurofins Scientific S.E.
• Bio Rad Laboratories, Inc.
• Other Key Players
To Know More, Click Here@ https://www.maximizemarketresearch.com/request-sample/100383
Regional Analysis:
Global, North America, Europe, Asia-Pacific, the Middle East, Africa, and South America market share statistics are accessible individually. Analysts at Maximize evaluate competitive strengths and conduct competitive analysis for each competitor individually.
COVID-19 Impact Analysis on Clinical Oncology Next-Generation Sequencing Market:
Aerospace and defense, agriculture, automobiles, retail and e-commerce, energy and power, healthcare, packaging, mining, electronics, banking, financial services, and insurance, among other industries, have all been affected by the COVID-19 outbreak. COVID-19 has had an impact on the Clinical Oncology Next-Generation Sequencing Market in general, as well as the growth rate in 2019-2020, as the impact of COVID-19 spread. Our most recent inquiry, opinions, and bits of knowledge on the market are critical to the businesses and associations in the Cardiac Resynchronization Therapy Systems industry,
Key Questions Answered in the Clinical Oncology Next-Generation Sequencing Market Report are:
- Which segment grabbed the largest share in the Clinical Oncology Next-Generation Sequencing Market?
- What was the competitive scenario of the Clinical Oncology Next-Generation Sequencing Market in 2023?
- Which are the key factors responsible for the Clinical Oncology Next-Generation Sequencing Market growth?
- Which region held the maximum share in the Clinical Oncology Next-Generation Sequencing Market in 2023?
About Us
Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.
Our Address
- MAXIMIZE MARKET RESEARCH PVT. LTD.
- ⮝ 3rd Floor, Navale IT park Phase 2,
- Pune Banglore Highway, Narhe
- Pune, Maharashtra 411041, India.
- ✆ +91 9607365656
- 🖂 [email protected]
- www.maximizemarketresearch.com
